ID | 1047 |
Name of the vaccine | Adacel |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 10 to 64 years |
Description of the vaccine | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine adsorbed (Tdap vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2005 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | The protective efficacy against mild pertussis was 77.9%. |
Vaccine formulation | Suspension for injection |
Dosage | Single 0.5 mL injection. First dose and Wound Management - 5 years. A repeat vaccination - 8 years. |
Mechanism of action | Not clearly defined. |
Route of administration | Intramuscular |
Indications | Active booster immunization against tetanus, diphtheria and pertussis. |
Export | Distributed by - Sanofi Pasteur Inc., USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria and tetanus. |
Side effects of vaccine | Injection site pain, swelling and erythema, myalgia, headache, malaise, body ache and tiredness. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/119862/download |
Other name | NA |
Additional Links | NA
|